Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of subcutaneous QGE031 in allergic asthma (extension of CQGE031B2201)
2013-003683-31Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ligelizumab in asthma and allergic asthma, sponsored by Novartis. Primary endpoints: Adverse events and Serious adverse events. Started Dec 2013; status: terminated.
02
Drugs
ligelizumab
03
Conditions
asthmaallergic asthma
Beyond the preview
Go deeper on 2013-003683-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003683-31.